Integrates receptor mapping, molecular profiling and behavioral assays across postmortem and rodent models to probe synaptic and neuroimmune drivers of cognition and affect. Focus on glutamate, GABA, cholinergic and endocannabinoid systems to inform therapeutic targets in schizophrenia, depression and Alzheimer’s.